

Supplemental Amendment and Response
Serial No.: 09/780,142
Page 2 of 6

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions of the claims pending in this application. Claims 33 and 41 are amended herein without any intent of disclaiming equivalents thereof.

1-32 (Cancelled)

33. (Currently Amended) A method of treating enhancing closure of unwanted choroidal neovasculature comprising endothelial cells in a mammal, the method comprising the steps of:

- (a) administering to the mammal an anti-angiogenesis factor in an amount sufficient to permit an effective amount to localize in the choroidal neovasculature, wherein the anti-angiogenesis factor is selected from the group consisting of angiostatin and an antibody that binds preferentially to vascular endothelial growth factor;
- (b) administering to the mammal after step (a) an amount of a tetrapyrrole derivative photosensitizer sufficient to permit an effective amount to localize in the choroidal neovasculature, wherein the photosensitizer is selected from the group consisting of lutetium texaphyrin and benzoporphyrin derivative, and wherein the anti-angiogenesis factor and the tetrapyrrole derivative photosensitizer are not coupled to one another; and
- (c) irradiating the choroidal neovasculature with laser light such that the light is absorbed by the photosensitizer so as to damage endothelial cells and occlude the choroidal neovasculature, wherein the occlusion caused by step (a) is synergistic with the occlusion caused by steps (b) and (c) thereby enhancing closure of the unwanted choroidal neovasculature.

34. (Previously Presented) The method of claim 33, wherein the mammal is a primate.

35. (Previously Presented) The method of claim 34, wherein the primate is a human.

Supplemental Amendment and Response

Serial No.: 09/780,142

Page 3 of 6

36-38. (Cancelled)

39. (Previously Presented) The method of claim 33, wherein the method more selectively occludes choroidal neovasculature relative to the same treatment lacking administration of the anti-angiogenesis factor.
40. (Previously Presented) The method of claim 33, wherein the method ameliorates the symptoms of age-related macular degeneration.
41. (Currently Amended) A method of ~~treating enhancing closure of~~ unwanted choroidal neovasculature comprising endothelial cells in a mammal, the method comprising the steps of:
 - (a) administering to the mammal an anti-angiogenesis factor in an amount sufficient to permit an effective amount to localize in the choroidal neovasculature, wherein the anti-angiogenesis factor is selected from the group consisting of angiostatin and an antibody that binds preferentially to vascular endothelial growth factor;
 - (b) administering to the mammal after step (a) an amount of a tetrapyrrole derivative photosensitizer sufficient to permit an effective amount to localize in the choroidal neovasculature, wherein the photosensitizer is selected from the group consisting of lutetium texaphyrin and benzoporphyrin derivative; and
 - (c) irradiating the choroidal neovasculature with laser light such that the light is absorbed by the photosensitizer so as to occlude the choroidal neovasculature, wherein damage to the endothelial cells resulting from the combination of steps (a), (b), and (c) is greater than that resulting only from the sum of steps (a), (b) and (c).
42. (Previously Presented) The method of claim 41, wherein the mammal is a primate.
43. (Previously Presented) The method of claim 42, wherein the primate is a human.
- 44-46. (Cancelled)

Supplemental Amendment and Response

Serial No.: 09/780,142

Page 4 of 6

47. (Previously Presented) The method of claim 41, wherein occlusion of the choroidal neovasculature resulting from steps (a), (b), and (c) is greater than that resulting from steps (b) and (c) alone.
48. (Previously Presented) The method of claim 41, wherein the method more selectively occludes choroidal neovasculature relative to the same treatment lacking administration of the anti-angiogenesis factor.
49. (Previously Presented) The method of claim 41, wherein the method ameliorates the symptoms of age-related macular degeneration.